Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study
The preliminary data suggest psilocybin is safe, well-tolerated, and can be feasibly investigated in a supervised medical setting in older adults as a prospective treatment for aMCI.
Authors
- Alastair J. Flint (ORCID: https://orcid.org/0000-0001-6806-0235)
- Philip Gerretsen (ORCID: https://orcid.org/0000-0003-4053-6814)
- Fumihiko Ueno (ORCID: https://orcid.org/0000-0002-2547-7943)
- Jianmeng Song (ORCID: https://orcid.org/0000-0001-8223-8845)
- Vincenzo Deluca
- Ishrat Husain
- Christopher Bowie
- Shannen Kyte (ORCID: https://orcid.org/0009-0008-0842-8411)
- Danielle Bukovsky
- Ariel Graff‐Guerrero
- Edgardo Torres‐Carmona
- Aron Amaev
Institutions
- University Health Network (CA)
- Centre for Addiction and Mental Health (CA)
- University of Toronto (CA)
- Queen's University (CA)
- Toronto Dementia Research Alliance (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_101101
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00